ArriVent BioPharma, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
18 CAMPUS BLVD., NEWTOWN SQUARE, PA, 19073-3269
Mailing Address
18 CAMPUS BLVD., NEWTOWN SQUARE, PA, 19073-3269
Phone
240-780-6356
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 5, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| 10-K Annual financial report | March 5, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
Annual Reports
10-K
March 5, 2026
- Lead candidate Firmonertinib is in clinical development, targeting oncology or rare diseases.
- Strategic partnerships established with Lepu Biopharma, Aarvik Pharmaceuticals Inc., and Shanghai Allist Pharmaceuticals Co. Ltd.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.